153 related articles for article (PubMed ID: 23916860)
21. Ezogabine: development and role in the management of epileptic seizures.
Verma A; Kumar R; Kumar M
Mini Rev Med Chem; 2013 Apr; 13(5):697-705. PubMed ID: 22931529
[TBL] [Abstract][Full Text] [Related]
22. Ring chromosome 20 syndrome without deletions of the subtelomeric and CHRNA4--KCNQ2 genes loci.
Elghezal H; Hannachi H; Mougou S; Kammoun H; Triki C; Saad A
Eur J Med Genet; 2007; 50(6):441-5. PubMed ID: 17851150
[TBL] [Abstract][Full Text] [Related]
23. Retigabine for partial onset seizures.
Rheims S; Ryvlin P
Expert Rev Neurother; 2012 May; 12(5):509-17. PubMed ID: 22550979
[TBL] [Abstract][Full Text] [Related]
24. Ezogabine (Potiga) toxicity.
Med Lett Drugs Ther; 2013 Nov; 55(1430):96. PubMed ID: 24276503
[No Abstract] [Full Text] [Related]
25. Ring chromosome 20 syndrome: electroclinical description of six patients and review of the literature.
Elens I; Vanrykel K; De Waele L; Jansen K; Segeren M; Van Paesschen W; Ceulemans B; Boel M; Frijns JP; Buyse G; Lagae L
Epilepsy Behav; 2012 Apr; 23(4):409-14. PubMed ID: 22424860
[TBL] [Abstract][Full Text] [Related]
26. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns.
Singh NA; Charlier C; Stauffer D; DuPont BR; Leach RJ; Melis R; Ronen GM; Bjerre I; Quattlebaum T; Murphy JV; McHarg ML; Gagnon D; Rosales TO; Peiffer A; Anderson VE; Leppert M
Nat Genet; 1998 Jan; 18(1):25-9. PubMed ID: 9425895
[TBL] [Abstract][Full Text] [Related]
27. Ezogabine: a novel antiepileptic for adjunctive treatment of partial-onset seizures.
Amabile CM; Vasudevan A
Pharmacotherapy; 2013 Feb; 33(2):187-94. PubMed ID: 23386597
[TBL] [Abstract][Full Text] [Related]
28. Frontal motor seizure following non-convulsive status epilepticus in ring chromosome 20 syndrome.
Kamoun FF; Ellouz EJ; Hsairi IG; Triki CC
Neurosciences (Riyadh); 2012 Jan; 17(1):74-7. PubMed ID: 22246017
[TBL] [Abstract][Full Text] [Related]
29. Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties.
Peretz A; Degani N; Nachman R; Uziyel Y; Gibor G; Shabat D; Attali B
Mol Pharmacol; 2005 Apr; 67(4):1053-66. PubMed ID: 15598972
[TBL] [Abstract][Full Text] [Related]
30. New association between ring chromosome 20 syndrome and hypomelanosis of Ito.
Cappanera S; Passamonti C; Zamponi N
Pediatr Neurol; 2011 Nov; 45(5):341-3. PubMed ID: 22000318
[TBL] [Abstract][Full Text] [Related]
31. A potassium channel, the M-channel, as a therapeutic target.
Surti TS; Jan LY
Curr Opin Investig Drugs; 2005 Jul; 6(7):704-11. PubMed ID: 16044666
[TBL] [Abstract][Full Text] [Related]
32. Clobazam, ezogabine, and tafluprost.
Hussar DA; Hallinan SE
J Am Pharm Assoc (2003); 2012; 52(4):546-50. PubMed ID: 22825237
[No Abstract] [Full Text] [Related]
33. Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells.
Tatulian L; Brown DA
J Physiol; 2003 May; 549(Pt 1):57-63. PubMed ID: 12702739
[TBL] [Abstract][Full Text] [Related]
34. KCNQ2/3 openers show differential selectivity and site of action across multiple KCNQ channels.
Zhang D; Thimmapaya R; Zhang XF; Anderson DJ; Baranowski JL; Scanio M; Perez-Medrano A; Peddi S; Wang Z; Patel JR; DeGoey DA; Gopalakrishnan M; Honore P; Yao BB; Surowy CS
J Neurosci Methods; 2011 Aug; 200(1):54-62. PubMed ID: 21723881
[TBL] [Abstract][Full Text] [Related]
35. The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels.
Brickel N; Gandhi P; VanLandingham K; Hammond J; DeRossett S
Epilepsia; 2012 Apr; 53(4):606-12. PubMed ID: 22428574
[TBL] [Abstract][Full Text] [Related]
36. Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder.
Tan A; Costi S; Morris LS; Van Dam NT; Kautz M; Whitton AE; Friedman AK; Collins KA; Ahle G; Chadha N; Do B; Pizzagalli DA; Iosifescu DV; Nestler EJ; Han MH; Murrough JW
Mol Psychiatry; 2020 Jun; 25(6):1323-1333. PubMed ID: 30385872
[TBL] [Abstract][Full Text] [Related]
37. Ezogabine: an evaluation of its efficacy and safety as adjunctive therapy for partial-onset seizures in adults.
Yamada M; Welty TE
Ann Pharmacother; 2012 Oct; 46(10):1358-67. PubMed ID: 22991134
[TBL] [Abstract][Full Text] [Related]
38. Ezogabine (KCNQ2/3 channel opener) prevents delayed activation of meningeal nociceptors if given before but not after the occurrence of cortical spreading depression.
Zhang X; Jakubowski M; Buettner C; Kainz V; Gold M; Burstein R
Epilepsy Behav; 2013 Aug; 28(2):243-8. PubMed ID: 23562239
[TBL] [Abstract][Full Text] [Related]
39. [Retigabine. A novel anticonvulsant drug for the adjunctive treatment of partial seizures].
Hecht B
Med Monatsschr Pharm; 2012 May; 35(5):166-71. PubMed ID: 22624350
[No Abstract] [Full Text] [Related]
40. KCNQ2, the first gene found to be mutated in human generalized idiopathic epilepsy.
Steinlein OK; Jentsch TJ
Pathol Biol (Paris); 1998 Nov; 46(9):683-4. PubMed ID: 9885816
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
